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ABSTRACT 
Even though Tulbaghia violacea has been used to treat and manage epilepsy in South Africa by 
traditional medicine practitioners, no evidence in any literature has shown any scientific scrutiny 
of the effectiveness of the plant species in therapy. This project was intended, therefore, to 
investigate the anticonvulsant effect of the leaf methanol extract of Tulbaghia violacea by 
studying its effect against tonic convulsion induced by either pentylenetetrazole (PTZ), 
bicuculline, picrotoxin, strychnine  or N-methyl-DL-aspartic acid (NMDLA) in mice. Qualitative 
phytochemical analysis, acute toxicity and HPLC studies were also carried out on the plant 
species. 
The doses of 200 (mg/kg, i.p.) and 400 (mg/kg, i.p.) of the leaf methanol extract of T. Violacae 
significantly delayed the onset of PTZ (100 mg/kg, i.p.)-induced tonic convulsion in a dose 
dependent manner. Leaf methanol extract of the plant species (200 mg/kg, i.p.) did not affect the 
incidence of PTZ (100 mg/kg, i.p.)-induced tonic convulsion while 400 mg/kg (i.p.) protected 
only one mouse against the tonic convulsion. Leaf methanol extract of Tulbaghia violacea 
(100mg/kg, i.p.) did not significantly affect the onset or incidence of PTZ (100 mg/kg, i.p.)-
induce tonic convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.) and 
muscimol (2mg/kg, i.p.) significantly delayed the onset of PTZ (100 mg/kg, i.p.)-induced tonic 
convulsion and also significantly reduced the number of animals convulsing. Muscimol (0.2 
mg/kg, i.p.) did not significantly affect the onset or incidence of PTZ (100 mg/kg, i.p.)-induced 
tonic convulsion. However, combined therapy of sub effective doses of the leaf methanol extract 
of T. Violacea (100 mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p.) significantly delayed the onset of 
PTZ (100mg/kg, i.p.)-induced tonic convulsion and but did not significantly reduce the number 
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of animals convulsing. The combined therapy of sub effective doses of the leaf methanol extract 
of T. violacea (100 mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p.) protected two of the mice against 
the tonic convulsion. Leaf methanol extract of Tulbaghia violacea (100-400 mg/kg, i.p.) 
significantly and dose dependently delayed the onset of tonic convulsion produced by bicuculline 
(30 mg/kg, i.p.), picrotoxin (20 mg/kg, i.p.) or NMDLA (400 mg/kg, i.p.)-induced tonic 
convulsion but did not affect the incidence of any of the convulsions. Phenobarbitone (12 mg/kg, 
i.p.), diazepam (0.5 mg/kg, i.p.) or muscimol (2 mg/kg, i.p.) significantly delayed the onset of
bicuculline (30 mg/kg, i.p.) or picrotoxin (20 mg/kg, i.p.)-induced tonic convulsion and also 
significantly reduced the number of animals convulsing. Phenobarbitone (12 mg/kg, i.p.) or 
diazepam (0.5 mg/kg, i.p.) did affect significantly affect the onset or incidence of NMDLA (400 
mg/kg, i.p.)-induced tonic convulsion. LY233053 (5 mg/kg, i.p.) significantly delayed the onset 
of tonic convulsion produced by NMDLA (400 mg/kg, i.p.) and also significantly reduced the 
number of animals convulsing. Leaf methanol extract of Tulbaghia violacea (200 and 400 
mg/kg, i.p.) significantly delayed the onset of strychnine (2 mg/kg, i.p.)-induced tonic convulsion 
but did not significantly affect the number of mice convulsing. The dose of 100 mg/kg (i.p.) of 
leaf methanol extract of T. violacea did not significantly affect the onset or incidence of 
strychnine (2 mg/kg, i.p.)-induced tonic convulsion. Phenobarbitone (12 mg/kg, i.p.) 
significantly delayed the onset of strychnine (2 mg/kg, i.p.)-induced tonic convulsion and also 
significantly reduced the number of animals convulsing. Diazepam (0.5 mg/kg, i.p.) did not 
significantly delay the onset of strychnine (2 mg/kg, i.p.)-induced tonic convulsion and also did 
not significantly affect the number of mice convulsing. Phenytoin (30 mg/kg, i.p.) or DMSO 
(0.25 ml, i.p.) did not significantly affect the onset or incidence of bicuculline (30 mg/kg, i.p.), 
picrotoxin, strychnine or NMDLA-induced tonic convulsion. The qualitative phytochemical 
 
 
 
 
xii 
analysis of the plant species showed the presence of alkaloids, saponins, cardiac glycosides, 
flavonoids, triterpene steroids, quinones and tannins. The LD50 value obtained following oral 
administration of the leaf methanol extract of Tulbaghia violacea may be greater than 4000 
mg/kg. The HPLC fingerprint of the leaf methanol extract of Tulbaghia violacea showed distinct 
peaks at the following retention times, 2.911, 3.269, 4.010, 7.597, and 15.122 min. The results 
obtained in this study indicate that the leaf methanol extract of Tulbaghia violacea has 
anticonvulsant activity. The results obtained also indicate that GABA, glutamic acid and glycine 
mechanisms may probably be involved in the anticonvulsant activity of the plant extract. The 
relatively high LD50 obtained for the plant species, given orally, indicate that it is safe in mice. 
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Chapter 1 
Introduction 
Epilepsy is a chronic neurological disorder characterized by spontaneous recurrent seizures 
(Chang and Lowenstein, 2003). It is one of the most common neurological disorders affecting 
approximately 50 million people worldwide (De Boer et al., 2008; van Mierlo et al., 2014), 
mainly in developing countries (Perucca et al., 2001; Preux and Druet-Cabanac, 2005). People 
with epilepsy (PWE) usually conceal their condition due to the fear of stigmatization and 
discrimination (Hung, 2009). There is as yet no known cure for epilepsy but it can be controlled 
(Boison, 2010). Approximately one-third ofPWE have drug-resistant seizures (Kwan and Brodie, 
2000) and less than 50% of affected people in developing countries receive medication (Shibre et 
al., 2006).Even newer anti-epileptic drugs (AEDs)are reported to have significant central nervous 
system (CNS) side-effects including decreased cognitive abilities and psychiatric complications 
(Schmidt, 2009). 
In some Asian and African countries, up to 80% of the population relies on traditional (folk) 
medicine for their primary health care needs (Kayne, 2009), possibly due to the high cost of 
conventional medication. In South Africa, approximately three million people in both urban and 
rural areas are reported to be reliant on traditional medicine exclusively or in combination with 
Western medicine (Jäger et al., 2005; Govender et al., 2006). Researchers identified 122 
compounds used in mainstream medicine which were derived from ethno medical plant sources, 
80% of which were used in the same or related manner as the traditional ethnomedical use 
(Browner, 1985; Van Wyk et al., 1997). One South African study found that some PWE 
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combinedWestern and traditional medicines for epilepsy treatment (Keikelame and Swartz, 
2007). 
Although natural products are widely used by PWE all over the world, there is currently little 
evidence of safety and efficacy to scientifically justify their use. Raskin (2003) acknowledged 
that plant-derived compounds are excellent sources for novel pharmaceutical products while 
Ekstein and Schachter (2010) reported that natural products with a long history of medicinal use 
against epilepsy should be further tested using systematic pre-clinical methods in PWE to 
confirm their potential as new treatments for epilepsy.  
According to the World Health Organization, scientific evidence to evaluate safety and 
effectiveness of traditional medicine is limited (Tilburt and Kaptchuk, 2008). Tulbaghia violacea 
is a safe and potent medicinal herb widely used against various ailments (Saibu et al., 2015) but 
no previous study has been reported on its anti-convulsant activity. However, Allium sativum, a 
member of its family, has been shown to have potent anti-convulsant activity (Advani et al., 
2011) hence one of the aims of this research is to evaluate the anti-convulsant activity and safety 
of Tulbaghia violacea in mice. 
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Chapter 2 
Literature review 
2.1. Brief epidemiology 
Epilepsy is the most common neurological disorder in the world affecting approximately 50 
million people worldwide (approximately 1% of world population), the majority (80-85%) of 
whom live in developing countries (Preux and Druet-Cabanac, 2005; Van Mierlo et al., 2014). 
Epidemiologic studies are generally considered important to identify the public health and 
healthcare priorities relating to epilepsy, including prevention, education, early detection, 
treatment and service needs (Jallon, 2002; Thurman et al., 2011). Seasonal variations in epileptic 
seizures have been reported in previous studies, with a reduction in seizures occurring during 
summer (Clemens et al., 2013). Similarly, seasonal variations in epilepsy births have been 
reported, with most births occurring in winter than in summer (Procopio et al., 1997; Procopio et 
al., 2006). 
In developed countries the prevalence of epilepsy is 4-10 people per 1000 (Olafsson and Hauser, 
1999; Õun et al., 2003). In Europe the estimated prevalence of epilepsy in 2004 was 4.3-7.8 per 
1000 (Pugliatti et al., 2007) and 1.8% in Latin America (Mac et al., 2007). Country-specific 
prevalence rates are0.97%in the United Kingdom (Shorvon, 2010); 0.7% in Turkey (Onal et al., 
2002); 30% in Russia (Guekht et al., 2010) and 2% in Australia (Tellez‐Zenteno et al., 2004). In 
developing countries like Panama, Tanzania, Ecuador, India, Liberia, Nigeria, Colombia and 
Venezuela, the prevalence of epilepsy was estimated to be more than 10% (Osuntokun et al., 
1987; Leary et al., 1999) while in Africa as a whole, it is estimated at 2.2-58 per 1000 of the 
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population and accounts for the second or third most common reason for consultation and 
hospitalization (Ngugi et al., 2010). Studies in Arab and Middle East countries showed 
prevalence of 6.5 per 1000 in Saudi Arabia (Al Rajeh et al., 2001) and 0.9/1000 in Sudan 
(Younis, 1983; Perenchio et al., 2004), among others. In South Africa the lowest rate of epilepsy 
prevalence (2.2 per 1000 of population) is reported in urban areas while the highest rate (15 per 
1000 of population) is in rural areas (WHO, 2004). 
The high epilepsy prevalence often observed in rural areas than in urban areas is generally due to 
a number of factors including family history, home delivery, consanguinity, increased risk of 
infection and prenatal insults such as asphyxia (Jallon, 2002; Rajshekhar et al., 2006). Epilepsy 
prevalence also varies between male and female; in Asia, available data shows that epilepsy is 
less common in women than in men (Fong et al., 2003; Tran et al., 2006). Some African studies 
done in Egypt, Libya, Tunisia, Somalia, Djiboti, Comoros, Sudan and Mauritania indicate that 
epilepsy prevalence is higher in males than in females, possibly because of risky behaviour 
among males that could lead to severe head injuries (Preux and Druet-Cabanac, 2005; Khedr et 
al., 2013). The age-adjusted epilepsy prevalence has also been found to range from 2.7-40 per 
1000 depending on location (Reggio et al., 1996; Rocca et al., 2001). 
2.2. Risk Factors and Causes of Epilepsy 
Factors that predispose persons to developing seizures and epilepsy could be considered the risk 
factors of epilepsy and include genetic risk factor, positive family history of epilepsy, 
consanguinity, obstetric complications, toxemia, premature birth, low birth weight, neonatal 
seizures, asphyxia, pre-eclampsia, febrile convulsions, severe head trauma, maternal nicotine 
use, history of stroke, neurocysticercosis and excess alcohol (Casetta 2002; Nsengiyumva et al., 
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2003; Edwards et al., 2008). Epilepsy symptoms can manifest at any age and may be idiopathic 
or symptomatic (Chokroverty, 1996). 
2.3. Types of Epilepsy  
Understanding the type ofseizure is a crucial step to effective management of epilepsy as this 
determines the treatment or surgical approaches to adopt (Rudzinski and Shih, 2011). 
International Classification of Epilepsy (ICE) related to seizure disorders suggests three main 
types (Figure 1) vizpartial seizures, generalized seizures and unclassified epileptic seizures 
(Chokroverty, 1996; Dekker, 2002). 
 
Figure 1: Classification of epilepsy 
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2.3.1. Partial (focal) seizures  
In this type of epilepsy, seizures are caused by abnormal electrical disturbances in only a part of 
the brain and these disturbances may or may not spread to other parts (Figure 2). These types of 
seizures can be classified into simple partial seizures and complex partial seizures, both of which 
can lead to generalized seizures (Dekker, 2002; Rudzinski and Shih, 2011). 
 
Figure 2: A partial (focal) seizure activity starts in one area of the brain (www.epilepsy.org.au) 
2.3.1.1. Simple partial seizures 
In this type of epilepsy, there is no loss of consciousness and although patients may remember 
what happened, they may not be able to explain. The seizures emanate from the affected area in 
the brain such as temporal lobe (Jokeit and Schacher, 2004; Pellock and Duchowny, 2005). 
2.3.1.2. Complex partial seizures 
In complex partial seizures, there is an impairment of consciousness and the condition may start 
as a simple partial seizure but develops into a complex partial seizure or directly as a complex 
seizure with impairment of consciousness at the onset of the seizure (Berendt and Gram, 1999). 
The clinical manifestations of complex partial seizures depend on the brain region affected by 
abnormal electrical activity (Chokroverty, 1996). Complex partial seizures are likely to arise 
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from the temporal or frontal lobes but can also occur in occipital or parietal lobes (Rudzinski and 
Shih, 2011). 
2.3.2. Generalized Seizures  
Generalized seizures are a type of epilepsy that starts from both cerebral hemispheres of the 
brain (Figure 3). They are characterized by a complete loss of consciousness and happen 
suddenly and unexpectedly (Dekker, 2002). These seizures may occur with convulsion and 
prominent motor activity or no convulsion at all (Friedman and Sharieff, 2006). They are often 
classified into six different categories of which the primary generalized tonic-clonic seizure 
(GTCS) type is considered the most common. Although others are less common, all seizure 
categories might be seen in special epilepsy clinics (Friedman and Sharieff, 2006).  
 
Figure 3: Generalized seizures are associated with the involvement of both cerebral hemispheres of the brain 
(www.epilepsy.org.au) 
 
2.3.2.1. Absence seizures: This seizure type may sometimes be unrecognized and are 
characterized by a brief loss of consciousness with minimal or no changes in muscle tone, 
brief upward rotation of the eyes, blank stare and an interruption of on-going activity 
(Dekker, 2002; Sysoeva et al., 2014). 
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2.3.2.2. Myoclonic seizures: This seizure type is often considered to occur in special 
epileptic syndromes (Dekker, 2002; Rudzinski and Shih, 2011) and involves sudden 
unilateral or bilateral shock-like muscle contractions which could manifest as single jerks or 
repeated jerks over longer periods (Chokroverty, 1996). 
2.3.2.3. Clonic seizures: This type of seizures is often generalized and consists of non-
tonic repetitive rhythmic flexing and stretching of the limbs (Dekker, 2002; Rudzinski and 
Shih, 2011). 
2.3.2.4. Tonic seizures: These seizure types are characterized by an immediate loss of 
consciousness and often consist of a deviation of the eyes and head towards one side or even 
the rotation of the whole body (Dekker, 2002; Rudzinskiand Shih, 2011). There are often 
sudden sustained muscle contractions which fix the limbs in some strained position.  
2.3.2.5. Tonic-clonic seizures (GTCS): These seizures are characterised by loss 
consciousness and posture and are occasionally associated with screams. They could develop 
into the tonic phase (a generalized stiffness) characterized by spasm in all muscles of the 
trunk with the patient becoming bluish in colour due to impaired breathing (Dekker, 2002). 
Furthermore, the head is retracted, the arms are flexed and the legs become extended and 
after a while, the tonic stage may progress into a clonic phase with the patient having many 
jerks as a result of muscle contraction and relaxation (Dekker, 2002). The patient might bite 
his or her tongue, pass urine, or sometimes stool. At the end of the GTCS, the patient regains 
consciousness but may remain too tired and confused for a while (Chokroverty, 1996; 
Rudzinski and Shih, 2011). 
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2.3.2.6. Febrile seizures (FS): These are the most prevalent types of convulsion that 
affect children aged five months to five years. Approximately 3-5% of the children under six 
years of age worldwide have FS (Wallace et al., 1998). A study by Millar (2006) showed that 
up to 5% of children in North America and Western Europe experience at least one episode 
of febrile seizure before the age of six years. It is considered that a viral infection is the most 
common cause of febrile seizures (Principi and Esposito, 2013). 
2.3.3. Unclassified epileptic seizures  
In this category are seizures that defy classification due to the fact that they do not fit into the 
descriptions for well-established seizure categories, e.g. some neonatal seizures 
(Chokroverty, 1996; Rudzinski and Shih, 2011). 
2.3.4. Special syndromes  
This category consists of a group of signs and symptoms that can assist one identify epilepsy 
and epileptic syndromes, e.g. age at which seizures begin, sex, seizure type, presence of 
physical or learning disabilities, electroencephalogram (EEG) results (Chokroverty, 1996). 
The WHO estimates that there are three different types of epileptic disorders: idiopathic, 
symptomatic and cryptogenic disorders. Idiopathic disorders are mainly due to genetic 
factors with no symptoms of structural brain lesion or other neurological signs.  
Symptomatic disorder etiology is usually known to be due to a structural lesion in the brain 
while cryptogenic disorder is thought to be a set of symptoms with unknown etiology. 
According to the international league against epilepsy (Dreifuss, 1985; CoCaTotILA, 1989), 
this classification depends on family history, clinical neurophysiology and combination of 
seizure semiology (Olafssonet al., 2005). 
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2.4. Epilepsy neurochemistry 
The major neurotransmitters in the brain are glutamate (GLU), gamma-amino-butyric acid 
(GABA), acetylcholine (ACh), nor epinephrine (NE), dopamine, serotonin, and histamine. 
Other molecules, such as neuropeptides and hormones, play modulatory roles that modify 
neurotransmission over longer time periods (Bromfield, et al., 2006). Besides its high oxygen 
consumption which makes it particularly vulnerable to oxidative stress, the brain also has 
high unsaturated fatty acid (UFA) content which makes it an easy target of lipid per 
oxidation (Perry et al., 2002; Nunomura et al, 2012). The metabolic rate of glucose in the 
cerebrum is often used as an index of brain activity (Kim, 2015) and there is currently 
enough evidence from human and experimental models to support the involvement of 
oxidative stress during seizures and in the epileptogenesis process (Cárdenas-Rodríguez etal., 
2014). Thus, perturbations (an imbalance or dysfunction) in the synthesis or levels of 
neurochemicals in the brain will often result inillness (Pan et al., 2012). Some of the 
neurochemicals that may be affected in epilepsy are discussed in the sections below. 
2.4.1. Gamma amino butyric acid (GABA) 
GABA was first synthesized in 1883 and known as a plant and microbe metabolic product. In 
1950, however, GABA was discovered to be an integral part of the mammalian 
neurotransmitter system. Found mostly as Zwitter ion, it is synthesized in situ from the 
decarboxylation of glutamate by the enzyme glutamic acid decarboxylase (figure 4) since it 
does not penetrate the blood-brain barrier (Jorgensen, 2005).  
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Figure 4: GABA structure (A); GABA is synthesized from glutamate by the enzyme glutamic acid 
decarboxylase (GAD) (Jorgensen, 2005). 
The binding causes ion channels to open and allow for the flow of either negatively charged 
chloride ions into or positively charged potassium ions out of the cell. Depending on which 
ion channels open, the membrane potential is either hyperpolarized or depolarized. The 
GABA hypothesis suggests that epileptic patients have a low chronic seizure threshold, 
because they suffer from genetic or post-pathological GABA hypo-function. A corollary of 
the GABA hypothesis suggests that some anti-convulsant drugs act by restoring GABA 
function to normal states in epileptic humans or that anti-seizure drugs act by stimulating 
GABA activity (Rogawski, 2002). Drugs that act as agonists of GABA receptors (GABA 
analogues or GABAergic drugs), or drugs that increase the available amount of GABA 
normally have relaxing, anti-anxiety and anti-convulsant effects. The pharmacology and 
distribution of GABA receptors in the brain have been widely studied (Rang et al., 2012); 
these receptors are classified as follows: 
2.4.1.1. GABAAreceptors  
GABAA receptors are ionotropic receptors linked to ligand-gated ion channels. These are 
very important and most abundant fast inhibitory neurotransmitter receptors in the 
mammalian brain mostly activated by GABA and play very important rolesin the mechanism 
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of action of many drugs (Sieghart and Sperk. 2002; Ding et al., 2014).The active site of the 
GABAA receptor is the binding site for GABA and several drugs such as muscimol and 
bicuculline (Rang et al., 2012).  
2.4.1.2. GABAC receptors  
GABAC receptors are GABA-gated chloride channels considered a sub-class of GABAA 
receptors. Although GABAC receptors are so similar to GABAA receptors, there are many 
physiological and pharmacological differences which distinguish GABAA from GABAB 
receptors (Bormann, 2000; Johnston et al., 2003).  
2.4.1.3. GABAB receptors 
GABAB receptors are G protein-coupled receptors (metabotropic receptors) widely 
distributed in the central and autonomic nervous systems (Bowery et al, 1981). Binding of 
the GABA neurotransmitter to the GABAB receptors causes inhibition of membrane 
excitability as K+ channels open while Ca++ channels close (Jorgensen, 2005). 
2.4.1.4. GABA transporters  
GABA transporters are divided into four types: GAT-1, GAT-2, GAT-3 and BGT-1 (Conti et 
al., 2004) distributed in various amounts throughout the developing human nervous system 
(Borden 1996). GAT-1 and GAT-3 arethe main sub-types in neurons and are considered the 
most pertinent to GABAergic neurotransmission (Roettger and Amara, 1999). GAT-2 and 
BGT-1 are fewer in the CNS and are less important for GABAergic neurotransmission 
(Borden 1996; Olsen et al., 1999).  
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2.4.2. Glutamate neurotransmitter 
Glutamate is considereda principal excitatory amino acid neurotransmitter in the mammalian 
brain known to play an important role in neural activation (Sundaram et al., 2012). There are 
two types of glutamate receptors: ion tropic and metabotropic receptors (Pin and Duvosin, 
1995; Pinto et al., 2014). 
2.4.2.1. Ionotropic glutamate receptors  
Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels which are abundant in 
the vertebrate central nervous system (CNS) and mediate excitatory neurotransmission (Pinto 
et al., 2014). There are several types of iGluRs, including N-methyl-D-aspartate (NMDA), α-
amino-3- hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) and kainite (KA) (Santiago 
et al., 2008). Mediation of these receptors for fast excitatory transmission in neurons occurs 
via the flow of the cations K+, Na2+ and sometimes Ca2+ in response to glutamate binding 
leading to excitation (Pinto et al., 2014). 
2.4.2.2. Metabotropic glutamate receptors  
Metabotropic glutamate receptors (mGlurs) are many in the peripheral nervous system (PNS) 
and the CNS and show homology in different animal species (Nicoletti et al., 2011; 
Tharmalingam et al., 2012). The mGlurs are often divided into three sub-groups (Groups I, II 
and III) according to such factors as physiological activity, sequence homology and 
pharmacological profile. Group I receptors include the sub-types mGlu1 and mGlu5; Group 
II receptors include mGlu2 and mGlu3 while Group IIIreceptors include mGlu4, mGlu6, 
mGlu7 and mGlu8 (Niswender and Conn, 2010). The binding of glutamate neurotransmitter 
to glutamate receptors results in excitation (Harvey and Shahid, 2012). 
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2.4.2.3. Glutamate transporters 
Glutamate is the main excitatory neurotransmitter in the mammalian CNS. Chemically, 
glutamate is synthesized from glutamine supplied by glial cells and then packaged in the 
synaptic vesicles via vesicular glutamate transporters. Glutamate plays an important role in 
several physiological processes in the CNS including learning and memory (Yang et al., 
2011; Sundaram et al., 2012). Its mechanism of action is via binding with its receptors 
(iGluRs and mGlurs) (Figure 5). There are five sub-types ofglutamate transporters in the 
mammalian CNS, the excitatory amino acid transporters (EAAT 1-5). Glutamate is cleared 
from synapses through excitatory amino acid transporters (EAATs) on neighbouring glial 
cells (EAAT1 and EAAT2, and to a lesser extent, on neurons (EAAT3 and EAAT4) (Seal 
and Amara, 1999).  
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Figure 5: Schematic representation glutamate (Glu) synthesis from glutamine supplied by glial cells and 
packaged in the synaptic vesicles viavesicular glutamate transporters (vGluTs).After release from the 
vesicles, glutamate binds to the glutamate receptors such as ionotropic glutamate receptors (NMDA and 
AMPA receptors) and metabotropic glutamate receptors (mGluR1 to mGluR8)on the membranes of  
neurons and glial cells, andthe receptors initiate different responses like membrane depolarization and 
modulation of local protein synthesis. Glutamate is cleared from the synapse through excitatory amino acid 
transporters (EAATs) on neighbouring glial cells (EAAT1 and EAAT2) and, to a lesser extent, on neurons 
(EAAT3 and EAAT4) (Popoli et al., 2012). 
 
2.4.3. Acetylcholine  
Although most epileptic seizures are characterized by an imbalance between GABA and 
glutamate i.e. excitation over inhibition, neuronal acetylcholine receptors (nAChRs) are 
known to play a role particularly in sleep-related epilepsy. This neurotransmitter imbalance 
may happen in parts of the brain (partial or focal seizures) or in the entire brain (generalized 
convulsive seizures).  
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2.5. Biomarkers  
A biomarker is defined as an objectively measured characteristic of a normal 
pharmacological response to medical treatment, biologic or pathologic process (Sahu et al., 
2011; Pitkanenet al., 2013). It is a term often used to refer to a protein measureable in blood 
or other body fluids whose concentration reflects the severity or presence of some disease 
state and in most cases helps to predict early stages of diseases for early diagnosis (Sahu et 
al., 2011). Changes in the re-organization of neuronal networks, in the number and functions 
of individual neurons, and in the sequential amendment of electrical properties of both the 
cells and the networks, could cause the firing of a large number of neurons leading to 
reoccurring seizures (Ben-Ari, 2001; Shukla and Prasad, 2012). 
A good understanding of biomarkers could help in the development of interventions to 
prevent epileptic seizures, stop its progression, prevent recurrence and potentially cure this 
condition (Pitkanen et al., 2013). Biomarkers of seizures are characterized by an increase in 
extracellular concentrations of glutathione, taurine and phosphoethanol amine in acute 
hippocampal slices and in organotypic slices cultures (Wallin et al., 1999; Wallin et al., 
2003) mainly as a reaction of glutamate receptor activation (Abbas, 2015). 
2.6. Epilepsy diagnosis 
The determination of paroxysmal event as an epileptic seizure is considered the first step of 
diagnosing epilepsy (Chitre, 2013)but medical history is equally very important in 
diagnosing epilepsy (Babtain, 2013). However it is known that mis-diagnosis of epilepsy is 
common as approximately 20% to 30% of patients seen at epilepsy clinics have been 
incorrectly diagnosed (Smith et al., 1999; Benbadis, 2009). The conditions that are most 
frequently confused with epilepsy include vasovagal syncope, cardiac syncope and non-
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epileptic attack disorder. Conditions that may mimic seizures include migraine, parasomnias, 
movement disorders, metabolic disturbances and panic disorder (Smith, 2012; Chitre, 2013). 
Access to complete details of the medical history is a very important step for the evaluation 
of seizures because there are several different causes of seizures, and there are many 
conditions to simulate a seizure (Friedman and Sharieff, 2006). 
Besides the medical history, an eye-witness account of events during the start of patient 
unconsciousness is very important to give a medication of the type of seizure involved 
(Benbadis, 2009). Additionally, a careful review of the person’s past medical history could 
indicate if there is a family history of cardiac arrhythmias or seizure, which may be related to 
such genetic disorder as idiopathic epilepsy syndrome (Karceski and Morrell, 2006). 
2.7. Laboratory testing  
Laboratory blood tests are often done as part of the routine process of determining the causes 
of diseases including seizures. It is known that a high fever or metabolic disturbances could 
cause seizures to occur. For example, an electrolyte disturbance as a result of severe 
diarrhoea or vomiting, or a glucose imbalance cause by low blood sugar, may also result in 
seizures (Edmonton Epilepsy Association, 2010).  
2.8. Electroencephalography (EEG) 
Electroencephalography (EEG) is the recording of brain electrical activity from the scalp 
which is often dependent on voltage differences between different points on the scalp, arising 
from excitatory and inhibitory postsynaptic potentials (Dietrich and Kanso, 2010). EEG is 
considered a very important test used for the diagnosis of epilepsy and is probably the most 
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specific method for defining the epileptogenic cortex. It has sensitivity and specificity, 
depending on age and recording procedures (Szilágyi et al., 2014).   
2.9. Magnetic Resonance Imaging (MRI) scans  
Magnetic Resonance Imaging (MRI) is a medical imaging technique which reveals possible 
structural lesions underlying epilepsy. It is used to assess co-morbidities and evaluate 
individuals with medically refractory epilepsy for potential operation. Considering the highly 
sensitive and accurate images that can be obtained from MRI, it has become a standard 
diagnostic procedure for epilepsy, as it can provide an accurate determination of 
epileptogenic lesions in medically refractory epilepsy (Duncan, 2009). All patients with 
epilepsy are advised to do MRI, except children and young people who have idiopathic 
generalized epilepsy which responds to treatment with AEDs (Winston et al., 2013). 
2.10. Pharmaceutical treatment of epilepsy  
The adequate treatment of epilepsy depends on the identification of the type of epilepsy and 
appropriate drugs. Mono-therapy has been recommended and shown to be very effective 
while single drug treatment is often advised as first option. If seizures remain uncontrolled, a 
second single drug treatment is suggested. Poly-therapy should only be contemplated after a 
third single drug therapy fails to control the seizures (Waller et al., 2005; SAMF, 2012).  
2.10.1. Anti-epileptic drugs (AEDs) 
AEDs are a fundamental treatment for epilepsy and seizures. The choice of AEDs depends 
on many factors such as the type of epilepsy, the risk of recurrence, age of the patient, drug 
toxicity, etc. (Friedman and Sharieff, 2006). Majority of AEDs do not cure epilepsy but 
merely control seizures by reducing or stopping their occurrence usually through changes in 
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brain neuronal activity (Boison, 2010). The different types of epilepsy require different drugs 
with different anti-epileptic effects for their treatment (Waller et al., 2005; Rang et al., 2012). 
In status epilepticus, lorazepam (i.v), diazepam (i.v/ rectal) or midazolam (buccal/intranasal) 
should first be given. However, if seizures are not controlled or do recur after 30 minutes of 
treatment in adults, then phenytoin (slow i.v) followed by phenobarbitone (rapid i.v) are 
recommended. If there is no further response then treatment with thiopental (iv) or propofol 
(iv) should follow (Waller et al., 2005; SAMF, 2012).  
In pregnancy, the lowest effective doses of AEDs are recommended alongside oral folic acid 
to prevent neural tube defect. If hepatic enzyme-inducing AEDs are used (e.g. phenytoin, 
carbamazepine or phenobarbitone), it is recommended that prophylactic oral vitamin K1 
should be given to the mother in the last 2 weeks of pregnancy and to the neonates, to avoid 
postpartum haemorrhage and neonatal bleeding respectively (Waller et al., 2005). 
2.10.2. Mechanisms of anticonvulsant drugs  
AEDs are a diverse group of pharmacological agents that control epileptic seizures through 
different mechanisms of action (Stefan and Feuerstein, 2007). Some AEDs (e.g. 
carbamazepine, phenytoin, valproate, lamotrigine, zonisamide, oxcarbazepine and 
topiramate) act through modulation of voltage-depedent ion channels by blocking sodium 
channels to reduce the ability of sodium-dependent action potentials and enhance steady state 
inactivation. Sodium channels in mammalian brains are complex protein sub-units (Catterall, 
2000) considered important targets of AEDs while others e.g pregabalin and ethosuximide, 
simply block calcium channels, mainly in partial and generalized seizures (Stafstrom, 2010). 
In addition, some AEDs (e.g. gabapentin, phenobarbital and benzodiazepines) are known 
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toenhance GABA activity (Figure 6), by increasing the proportion of bound GABA receptors 
that are in the long-duration active state (White et al., 2000). Other AEDs (e.g. lamotrigine) 
are known to block glutamate-mediated excitatory neurotransmission (Hernández-Díaza and 
Levin, 2014); the ionotropic glutamate receptors NMDA and AMPA, known to play 
important roles in epilepsy treatment, are important targets for AEDs (Rogawski, 1996; 
Löscher, 1998).  
 
Figure 6: Pharmacological substances (anti-epileptic drugs) bind to GABA 
receptors to modulate GABA effects (https://www.xbrain.co.uk/alpha-brain-
ingredientsgaba) 
2.10.3. Non-drug treatment  
Other methods that enhance treatment of epilepsy have been recommended. A number of 
non-drug approaches to therapy have been tried including biofeedback, hypnosis and surgery 
(Singer, 2001; Dewar and Pieters, 2015). Of all these, only surgery has gained widespread 
acceptance and for selected patients, neurosurgery offers a risky but effective cure for 
seizures. Surgery involves removal of an area of the brain responsible for seizures and is 
often attempted only when attacks appear from a ‘clear cut’ focal area and if seizures do not 
respond to medication (Günaydın et al., 2015). Evaluation for surgery is normally done by 
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many medical specialists: radiologists, neurologists, psychologists and neurophysiologists 
(Walker and Fish, 2009). 
Ketogenic diets which are high in fat and low in carbohydrates and proteins have been used 
for epilepsy in children not responding to conventional drug treatment. The diet is said to 
stimulate a fasting situation that is perceived by the brain as the feeling of hunger and allows 
the body to produce ketones which help suppress the epileptic condition (Kossoff, 2010). 
In spite of the large number of new AEDs available in the market today, there is still no cure 
for epilepsy (Boison, 2010). Many available drugs often have severe side effects and are 
highly pharmaco-resistant (Vajda, 2007). Most of these drugs do not also affect the 
underlying disease processes, thus there is a need to develop innovative therapeutic strategies 
based on knowledge of underlying molecular pathogenetic mechanisms (Boison, 2010). If 
the molecular pathways of epilepsy are well known, the phenotypic expression of epileptic 
seizures could be silenced. Gene silencing techniques aimed at over-expressing selected 
anticonvulsant molecules have been explored as therapeutic options for epilepsy (Riban et al, 
2009). 
The use of available convectional pharmaceutical products has yet to lead to an effective cure 
for epilepsy (Howard et al., 2011). Some of these products are unaffordable by epilepsy 
patients in most rural communities especially in Africa and Asia hence they resort to 
traditional medicines to manage their epileptic conditions (Van Wyk et al., 1997; Kayne, 
2009). Many of these traditional medicines are plant-derived and are known to contain potent 
bioactive compounds which are effective in the control of epileptic seizures. 
 
 
 
 
22 
 
2.11. Epilepsy and traditional medicine  
The World Health Organization (WHO) defines traditional medicine as "the knowledge, 
skills and practice of holistic care, recognized and accepted for its role in the maintenance of 
health and treatment of diseases. It is based on indigenous theories handed down from 
generation to generation for its beliefs and experiences (Zhang and WHO, 2000).  
The use of traditional medicine for the treatmentof epilepsy is widespread in developing 
countries and about two-thirds of the population of these countries relies heavily on 
traditional medicine treatment as their basic health care system (Farnsworth and Soejarto, 
1991). In developing countries like India, China and African countries, traditional medicine 
has been improved for the health care system and hasbecome more widespread to even 
developed countries (Fouche et al., 2008; Ashidi et al., 2010). 
Traditional herbal medicines have been used for thousands of years by millions of peoplein 
Africa, for the prevention and treatment of diseases (Cragg and Newman, 2005). In South 
Africa, an estimated 27 million people are reported to use indigenous traditional medicines 
particularly in KwaZulu-Natal where households are said to spend between 4% and 6% of 
their annual incomes on indigenous medicine and services (Mander, 1998). Many herbal 
medicines are efficacious and safe (Pearl et al., 2011), have a history of use for the treatment 
of neurological diseases (including epilepsy) and could enhance the effects of conventional 
anti-depressants (Ernst 1995; Adeyemi et al., 2007). 
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2.12. Tulbaghia violacea 
2.12.1. Ethnobotany and phytochemistry 
Tulbaghia violacea (T. violacea) is a bulbous plant with hairless leaves, and a white, fleshy 
stalk (Van Wyk et al., 1997). It has attractive violet flowers and long, hairless green leaves. 
T. violacea is known as “itswelelomlambo” in Xhosa, “wildeknoffel” in Afrikaans, 
“isihaqa”in Zulu and “sweet garlic, wild garlic or society garlic” in English (Street et al., 
2010; Saibu et al., 2015). T. violacea belongs to the Alliaceae family, which is the same 
family as onion and real garlic. Furthermore, T. violacea and garlic (Allium sativum) have the 
characteristic sulphur smell of garlic andthis plantis presumed to have the same biological 
activities and secondary (Bungu et al., 2006). 
Geographically, T. violacea is widely spread throughout Africa and is considered an 
indigenous plant to the Eastern Cape Province of South Africa where it grows on rocky 
grasslands. T. violacea has been used as a substitute for garlic and also as a medicinal plant 
for the treatment of various diseases (Ebrahim and Pool, 2010). 
2.12.2. Medicinal use of T. violacea 
T. violacea is extensively used as a medicinal plant for various disease conditions such as 
fever, tuberculosis, asthma, stomach problems, oesophageal cancer, fits and rheumatoid 
arthritis (Ebrahim and Pool, 2010; Ncube et al., 2011). Although T. violacea has many 
benefits as a traditional medicine, several adverse effects such as abdominal pain, intestinal 
mucosa sloughing as well as acute inflammation have been attributed to its use (Bungu et al., 
2006). 
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Figure 7: TulbaghiaviolaceaHarvalsoknown as society garlic. (A) Flowers, (B) Rhizomes and (C) Leaves 
(Khabbab, 2012) 
2.12.3. Experimental studies of T. violacea 
The potential anti-cancer activities of the methanolic extracts of T. violacea have been 
investigated in vitro and results showed that T. violacea leaves and bulbs significantly 
inhibited the growth of four cancer cell lines namely HT29 (colon cancer), HeLa (cervical 
cancer), WHCO3 (oesophageal) and MCF-7 (breast cancer) respectively (Bungu et al., 2006; 
Bachrach, 2012). 
A 
B C 
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The anti-hypertensive effects of T. violacea in animal models of both systolic and diastolic 
hypertension have been investigated (Raji et al., 2012) and T. violacea was found to induce 
significant reduction in systolic and diastolic hypertension and heart rate (HR) in 
spontaneously hypertensive Wistar rats (SHR) via inhibition of β1 adrenoceptors 
andangiotensin I converting enzyme (ACE). Mackraj et al. (2008) reported that the 
hypotensive effects of T. violacea could be secondary to a direct negative chronotropic effect 
on heart muscles.  
T. violacea has also been reported to have antimicrobial (antibacterial and antifungal) 
properties (McGaw et al., 2000; Motsei et al., 2003) especially against different microbial 
infections such as pulmonary tuberculosis, oral and ear infections (Lyantagaye, 2011; Aremu 
and Van Staden, 2013). 
2.12.4. Experimental studies of known anticonvulsant plants  
The anticonvulsant activities of some plants especially those in the Alliaceae family, have 
been reported (Advani et al., 2011) but there is no literature on the anti-convulsant effects of 
T. violacea. An understanding of the mechanisms of action of other anti-convulsant plants 
may help explain the mechanisms of action of T. violaceadue to chemical similarities. 
2.12.4.1. Allium sativum (garlic) 
Allium sativum (common name: garlic) belongs to the Alliaceae family, originated from 
central Asia and spread to the rest of the world. This plant has been widely used against 
various ailments and physiological disorders including lowering of blood cholesterol levels, 
improvement of cardiovascular diseases and antimicrobial effects (Ginter and Simko, 2009; 
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Londhe, 2014). The oil in garlic has been shown to have anti-convulsant effects which may 
be mediated by an increase in brain GABA content (Advani et al., 2011). 
2.12.4.2. Rutagraveolens (R. graveolens) 
R. graveolens belongs to the Rutaceae family and although it is indigenous to the 
Mediterranean region (Watt and Breyer-Brandwijk, 1962), it is currently a global medicinal 
plant in many countries including South Africa, with potent anticonvulsant effects (Palmer 
and Pitman, 1972; Van Wyk et al., 1997). This plant appears to exert its anticonvulsant 
activity by enhancing GABA neurotransmission (Ahmad and Amabeoku, 2013). 
2.12.4.3. Leonotisleonurus (L. leonurus) 
L. leonurus belongs to the Lamiaceae family of plants and is native to South Africa with 
wide distribution throughout the country. It is known as “Umuuyane” in Zulu and “Wilde 
dagga” in Afrikaans (Hutching et al., 1996; Van Wyk and Gerick, 2000). Traditionally, L. 
leonurus has been used via smoking, to relieve epilepsy convulsions. It is known to affect 
both the GABAergic and glutamatergic systems by delaying seizure latency (Bienvenu et al, 
2002). 
2.12.4.4. Persea Americana mill (P. Americana) 
P. Americanabelongs to the Lauraceae family of plants and is known by its common name 
“Avocado” (Ojewole and Amabeoku, 2006). It is native to Mexico, but is now used 
worldwide (Ross, 1999). It has been used as analgesic, anti-hypertensive, anti-tussive, anti-
diabetic and anti-inflammatory agents respectively (Antia et al., 2005; Owolabi et al., 2005). 
Avocado has also been used in African traditional medicine as an anti-convulsant 
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formulation to control childhood convulsions and its anti-convulsant effects are mediated by 
the enhancement of GABA release (Ojewole and Amabeoku, 2006). 
2.12.4.5. Cotyledon orbiculata (C. orbiculata) 
C. orbiculata belongs to the Crassulaceae family of plants and is found throughout South 
Africa. It is known as “Imphewula” in Xhosa, “Plakkie” in Afrikaans and “Seredile” in 
Sesotho and Tswana. In South Africa, it is used to treat several types of diseases such 
astoothache, earache, warts and epilepsy (Watt and Breyer-Brandwijk, 1962; Van Wyk et al., 
1997). Its anti-convulsant function involves delay of the onset of tonic convulsions which 
may suggest glutaminergic and GABAergic mechanism of action (Amabeoku et al., 2007).  
2.12.4.6. Zanthoxylumcapense (Z. capense) 
Z. capense belongs to the Rutaceae family of plants and is native to Southern Africa; 
commonly distributed from Zimbabwe to the Western Cape of South Africa (Palmer and 
Pitman, 1972; Van Wyk et al., 1997). It is known by different names in South Africa: small 
knobwood (in English), “kleinperdepram” (in Afrikaans), “umnungamabele” (in isiZulu) and 
“monokwane” (in seSotho). Z. capense is a widely used as a traditional medicine against 
different ailments, including stomach-ache, toothache, fever and epilepsy (Van Wyk et al., 
1997). This plant delays the onset of convulsions, which may suggest either or both of 
GABAergic and glutaminergic mechanisms (Amabeoku and Kinyua, 2010).  
2.12.4.7. Sutherlandia frutescens (S. frutescens)  
S. frutescens belongs to the Fabaceae family of plants and is widespread throughout 
Southern Africa, known by different names including Cancer bush (in English) and 
“Umwele” (in IsiZulu) (Van Wyk et al., 2000; Stander et al., 2007). In Southern Africa, S. 
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frutescens has been traditionally used for the treatment of childhood convulsions and 
epilepsy. Many studies have shown that this plant has the ability to delay the onset of 
convulsion either directly by acting on GABA at GABAergic receptors, or indirectly by 
enhancing or modulating GABAergic neurotransmission in the brain (Ojewole, 2008).  
2.12.4.8. Carissa edulis (C. edulis) 
C. edulis belongs to Apocynaceae family of botanicals and is known by different names 
including “Cizaki” in Nigeria, “Adishawel” in Somalia and “Num-num” in most Arabic 
countries (Hutchinson and Dalziel, 1963; Ya’u et al., 2008). C. edulis has been used 
traditionally for a wide variety of ailments including rheumatism, headache, gonorrhea, 
syphilis and epilepsy (Nedi et al., 2004). The anti-convulsant activity of this plant may be 
mediated via interaction with some substances like benzodiazepine to form GABA-
benzodiazepine receptor complex (Ya'u et al., 2008). 
2.12.4.9. Harpagophytumprocumbens DC (H.procumbens) 
H. procumbens belongs to the Pedaliaceae family of botanicals and is native to Southern 
Africa where it is known by different names such as “Wood spider” and “Devil's claw” (Van 
Wyk et al., 2002). H. procumdens has been widely used in South Africa as a traditional 
medicine for the treatment, management and/or control of hypertension, diabetes mellitus, 
gout, skin cancer, fever, infectious diseases, allergies, and osteoarthritis (Van Wyk and 
Gericke, 2000). This plant is used to treat epilepsy and childhood convulsions via enhancing 
GABAergic neurotransmission (MacDonald and Kelly, 1994; Mahomed and Ojewole, 2006). 
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2.12.4.10. Crinum Zeylanicum (C. Zeylanicum) 
C. zeylanicum is a member of the Amaryllidaceae family of botanicals widely used for the 
treatment of various diseases in the Dominican Republic especially malaria (Fennell and 
Staden, 2001). In Nigeria, this plant is used against childhood convulsions, epilepsy, general 
debility and malaria (Tijani et al., 2012). The anti-epileptic effects of C. zeylanicum may be 
via enhancement of GABAergic neurotransmission (Tijani et al., 2012) 
2.12.5. Potential anticonvulsant effects of T. violacea 
T. violacea shares similar chemical properties with most of the above-mentioned botanicals; 
hence it is possible that this plant also has anti-convulsant properties. However, the exact 
mechanisms through which T. violacea could exert its anti-convulsant effects are unknown, 
which informs the motivation for the current study. Garlic (Allium sativum) for instance, is 
known to contain volatile sulfur-containing flavour compounds which are responsible for its 
characteristic smell and taste. Most of these plants also contain alliinase enzymes known to 
play some role in stimulating the conversion of the odourless S-alk (en) yl-L-cysteine 
sulfoxides into the volatile thiosulfinates, with pyruvate and ammonia formed as by-products 
(Block, 1992; Koch and Lawson, 1996). 
2.12.6. Animal models of status epilepticus and convulsion  
Animal studies have long been used for scientific detection of pathogenesis, toxicity and 
treatment effects in various diseases (Oakley et al., 2008). The pathophysiology of seizures 
and epilepsy has also been widely studied using animal models which have provided useful 
information about the mechanisms of action of the various treatment methods currently in 
use against epilepsy (Epps and Weinshenker, 2013). The basic mechanisms underlying 
ictogenesis and epileptogenesis have been elucidated with animal studies, leading to the 
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discovery and pre-clinical development of novel AEDs (Löscher, 2011). White et al. (2006) 
suggested thatanimal studies are a more reliable way of establishing the efficacy and safety 
of AEDs before prescription for humanuse.  
2.12.6.1. Genetic animal models   
Epilepsy in humans is characterized by chronically recurring and spontaneous seizures with 
symptoms that have been induced in some animal models. Genetic factors contribute largely 
to the etiology of seizure disorders (Schauwecker, 2011), thus most of the animal models 
currently in use have inborn susceptibility to seizures (Löscher, 1984, 1992; Buchhalter, 
1993). A non-epileptic animal will not be a suitable chronic epilepsy model (Löscher, 2011). 
2.12.6.2. Non-epileptic animal models  
This type of model is slightly different to the epileptic animal models as it involves the use of 
convulsion-inducing agents e.g. pentylenetetazole (PTZ) to induce seizures. These models 
are also used to determine the mechanisms of action of new AEDs (Löscher, 2002; 2011); 
normal (non-epileptic) animals are usually administered a chemical such as PTZ, N-Methyl-
D-aspartic acid (NMDA) and pilocarpine, toinduce clonic or tonic–clonic seizures in animals 
similar to the condition in humans. 
2.12.6.3. BALB/c mice  
BALB/c mice are in-bred albino mice which have peculiar features, such as easy breeding 
and minimal weight difference between males and females. These mice have also been used 
for monoclonal antibody production and have also played an important role in oncology 
research (Oakley et al., 2008). 
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2.12.7. Objectives of the study 
Despite the wide use of T. violacea in traditional medicine for the treatment and management 
of many disease conditions (Saibu et al., 2015), little or no information exists in literature 
about the anti-convulsant potential of this plant. The present study therefore aims to 
investigate the mechanism of action by which the methanolic leaf extracts of T. violacea 
exerts its anti-convulsant effects in BALB/c mice. Animals will be injected with compounds 
known to inhibit GABA neurotransmission (pentylenetetrazole, bicuculline and picrotoxin-
PCN) as well aswith other compounds known to enhance glutamic acid neurotransmission 
(NMDLA) to induce convulsions. Treatment of the induced convulsions will then be done 
with different doses of the methanolic leaf extract of T. violacea. 
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Chapter 3 
Materials and Methods 
 
3.1   Plant Material 
 
3.1.1. Collection and identification of the plant 
 
Fresh leaves of Tulbaghia violacea were collected from Kirsten Bosch National Botanical 
Garden, South Africa, in March 2014. The identity of the leaves was confirmed by the curator of 
the Garden and a taxonomist, Mr F. Weitz, in the Department of Biodiversity and Conservation 
Biology, University of the Western Cape. A voucher specimen of T. volacea (Amebeoku 007) 
was then deposited in the Herbarium at the University of the Western Cape. 
3.1.2. Preparation of the leaf methanol extract of T. violacea 
 
The fresh leaves of the plant species were separated from branches of the plant, weighed (1.7 kg) 
and then washed with distilled water. They were dried in a ventilated oven at 35°C for 4 days.   
The dried leaves (818.1 g) were ground into fine powder (486 g) using the Waring Commercial 
laboratory blender. To prepare the methanolic leaf extract of T. violacea, sixty grams (60 g) of 
thedried powder was extracted in a Soxhlet extractor with 500 ml of methanol for 4 hours. The 
methanol filtrate obtained was evaporated to dryness using a Buchi RE11 rotavapor and Buchi 
461 water-bath and 5.83 g of crude methanol extract was obtained. This was then preserved in 
desiccators for further studies. Fresh solution of the crude leaf methanol extract of T. violacea 
was preparedon each day of the experiment by dissolving a weighed quantity of the crude 
methanol extract inaminimum volume of dimethylsulfoxide (DMSO) and then made up to the 
appropriate volume with physiological saline. The solution was injected intraperitoneally (i.p.) to 
mice in a volume of 1 ml/100 g of body weight of animal. 
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3.2. Animals 
 
Male and female albino mice were used for this study. The animals were bred in the Discipline 
of Pharmacology, School of Pharmacy, University of the Western Cape, South Africa and 
weighed between 18 g and 30 g. The mice were used in groups of eight for each dose of plant 
extract or drug and had access to food and water ad libitum. All animals were fasted for 16 hours 
during which they had access to water before the commencement of the experiments. Laboratory 
conditions were maintained at ambient temperature of 22±1oC, relative humidity of 55 ± 15% 
and 12 hours light/12 hours dark cycle atall times during the experiments. Each animal was used 
only once in the experiments. 
 
3.3. Drugs and Chemicals 
Strychnine (STN, Sigma Chemical Co),  pentylenetetrazole (PTZ, Sigma Chemical Co.), 
picrotoxin (PCN, Sigma Chemical Co.), N-methyl-DL-aspartic acid (NMDLA, Sigma Chemical 
Co.), phenobarbitone sodium (BDH Chemicals Ltd), LY233053 (Sigma  Chemical Co.), 
muscimol (Sigma Chemical Co.) and5,5 di-phenylhydantoin sodium salt (Phenytoin, Sigma 
Chemical Co.) were dissolved in physiological saline to the required volumes. (+) Bicuculline 
(Sigma Chemical Co.) was suspended in a minimum amount of Tween 80 and adjusted to the 
appropriate volume with physiological saline. Diazepam is the generic name for Valium (Roche, 
South Africa) was dissolved in a minimum amount of propylene glycol and made up to the 
appropriate volume with physiological saline. Dimethylsulfoxide (DMSO, Sigma Chemical Co.) 
solution was prepared by dissolving equal volume, used to dilute the plant extract, in an 
appropriate volume of physiological saline. All drugs were injected intraperitoneally (i.p.) in a 
volume of 1 ml/100 g of animal body weight. Equal volume injections of the appropriate 
vehicles such as physiological saline and DMSO were given to the control animals. Fresh 
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solutions of the plant extract or drugs were prepared on each day of the experiment. The doses of 
the methanolic leaf extract of T. violacea used were obtained from preliminary studies in our 
laboratory. The pre-treatment times following the administration of PTZ, bicuculline, PCN or 
NMDLA were 15 minutes (plant extract), 10 minutes (phenobarbitone), 20 minutes (diazepam), 
20 minutes (phenytoin), 30 minutes (LY233053), 1 hour (muscimol) and 15 minutes (DMSO 
solution), as obtained from previous studies (Amabeoku and Kinyua, 2010). 
3.4. Phytochemical analysis of Tulbaghiaviolacea 
Phytochemical analysis was performed on the samples of dried powdered leaf extracts of T. 
violacea using the methods of Harbone (1984) and Ikhiri et al. (1992) to screen for chemical 
compounds including alkaloids, Saponins, Reducing sugars, Flavonoids, Cardiac glycosides, 
Triterpene steroids, Quinones and Tannins. 
3.4.1 Alkaloids  
A sample of dried powdered leaves of T. violacea (0.5 g) was mixed with 10 ml of dilute 
hydrochloric acid (alcoholic) in a test tube and boiled for 5 minutes. The mixture was cooled and 
the debris was allowed to settle. The supernatant was filtered and1ml of the filtrate was 
transferred into another test tube into which three drops of Dragendorffs’ reagent was added, 
shaken and observed for the appearance of an orange-red spot and a precipitate which would 
indicate the presence of alkaloids. 
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3.4.2 Saponins 
A sample of driedpowdered leaves of T. violacea (0.4 g) was mixed with 4 ml of water in a clean 
test tube and shaken vigorously for 20 seconds. This was then observed for a persistent froth 
which would indicate the presence of Saponins. 
3.4.3 Reducing sugars  
A sample of dried powdered leaves of T. violacea (0.2 g) was boiled in 5ml of water and the 
mixture was cooled and filtered. An equal quantity (5ml) of Fehlings A and B solutions 1:1 was 
added to the filtrate (3 ml), heated in a water-bath, and then observed for a red-brownprecipitate 
formation which would indicate the presence of reducing sugars.  
3.4.4 Flavonoids. 
A sample of driedpowdered leaves of T. violacea (10 g) was boiled in 100 ml of water for 2 to 3 
minutes in a water-bath. The mixture was allowed to cool beforefiltration. The filtrate (3 ml) was 
put in a test tube to which 3 ml of acid-alcohol (Ethanol: Water: concentrated hydrochloric acid 
in a ratio of 1:1:1), solid magnesium (1 cm) and 1 ml of t-amyl alcohol were added. The mixture 
was then observed for a rose-orange or violet colour which would indicate the presence of 
flavonoids. 
3.4.5 Cardiac glycosides 
A sample of dried powdered leaves of T. violacea (0.5 g) was boiled in 5 ml of 70% ethyl alcohol 
for 2 minutes. The mixture was allowed to cool and then filtered. The filtrate (3 ml) was put in a 
small beaker and 10 ml of water and 5 ml of chloroform were added. It was then shaken and the 
lower chloroform layer separated and evaporated to dryness in a water-bath. The cooled chloroform 
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residue was dissolved in 3 ml of glacial acetic acid containing 0.1 ml of ferric chloride. The solution 
was carefully transferred to the surface of a 2 ml of sulphuric acid solution and observed for a 
reddish-brown layer at the interface while the upper layer may gradually acquire a bluish-green 
colour. These would indicate the presence of cardiac glycosides. 
3.4.6 Triterpene steroids  
A sample of dried powdered leaves of T. violacea (1 g) was extracted for 24 hours in 20 ml of 
ether. The resultant solution was filtered and 1 ml of the filtrate evaporated to dryness. The 
resultant residue was re-dissolved in several drops of acetyl anhydride to which several drops of 
dilute sulphuric acid were added and observed for a green colour change which would indicate 
the presence of triterpene steroids. 
3.4.7 Quinones 
A sample of dried powdered leaves of T. violacea (10 g) was moistened with a 10 % 
hydrochloric acid (HCl) solution and allowed to stand in ether: chloroform mixture (3:1, 40 ml). 
The mixture was filtered and 1 ml of the resultant filtrate was treated with 1 ml of 10 % sodium 
hydroxide (NaOH) solution. A red coloration would indicate the presence of quinones. 
3.4.8 Tannins 
A sample of dried powdered leaves of T. violacea (0.2 g) was boiled in 5 ml of water. The 
subsequent mixture was allowed to cool down and was filtered thereafter. The filtrate (2 ml) was 
put in a test-tube and 2-3 drops of 5% ferric chloride solution were added and observed for a 
blue-black precipitate which would indicate the presence of tannins. 
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3.5 High performance liquid chromatographic (HPLC) analysis  
Chromatographic system: Agilent 1200 system consisting of degassing system, quaternary pump, 
auto loading sampler, thermos tatted column compartment, diode array detector, fluorescence 
detector, analyse fraction collector and Agilent Chem. Station software; column: Phenomenex 
Luna (C18) 5μm and dimensions (250 cm x 4.6 mm). 
Chromatographic conditions: Mobile phase degassed with helium, solvent A: water-containing 
0.1% formic acid; solvent B: Acetonitrile-containing 0.1% formic acid, Mode: flow rate, 0.8 
ml/min; injection volume, 50 μl, detector, UV at 370 nm. The eluent was monitored at several 
wavelengths ranging from 210 to 370 nm, the specific wavelength of interest being 350 nm. The 
HPLC operating conditions were programmed to give the following: 0 minute, solvent B: 18%; 
15 minutes, solvent B: 25%; 20 minutes, solvent B: 35%, 30 minutes, solvent B: 90%. The run 
rate was 30 minutes. 
3.6 Pharmacological assessment 
3.6.1 Anticonvulsant activityassessment 
 
The method of Vellucci and Webster (1984) as modified by Amabeoku and Kinyua (2010), was 
used to evaluate the anti-convulsant activity of the methanolic leaf extract of T. violacea. The 
mice were acclimatized to their new environment by housing them singly in transparent perspex 
mouse cages 30 minutes before commencement of the experiment. Eight control animals were 
pre-treated for 15 minutes with physiological saline (0.25 ml, i.p.) and then administered 
separately with standard convulsant drugs including PCN (12 mg/kg, i.p.), PTZ (100 mg/kg, 
i.p.), bicuculline (40 mg/kg, i.p.) and N- methyl-DL-aspartic acid (NMDLA, 400 mg/kg, i.p.), to 
produce  tonic convulsion after 30 minutes. Seizures were manifested as tonic hind-limb 
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extensions. The onset time of tonic seizures and the proportion of animals convulsing or not 
convulsing were obtained during the 30-minutes observation period. Test animals (eight per 
group) were pre-treated with either the methanolic leaf extract of T. violacea (100-400 mg/kg, 
i.p.), phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.), phenytoin (30 mg/kg, i.p.), 
muscimol (0.2-2 mg/kg, i.p), LY233053 (5 mg/kg, i.p.) or DMSO (0.25 ml, i.p.) prior to the 
administration of any of the convulsant agents and the animals were also observed for 30 
minutes for tonic convulsion. The time of the onset of seizures and proportion of animals 
convulsing or not convulsing were obtained during the 30-minute observation period. The 
experiment was repeated with another group of eight mice pre-treated with combined sub-
effective doses of leaf methanol extract of T. violacea (100 mg/kg, i.p.) and muscimol (0.2 
mg/kg, i.p.) prior to the administration of PTZ (100 mg/kg, i.p.). The ability of the plant extract 
to prevent or prolong the onset of the tonic hind limb extensions was taken as an indication of 
anti-convulsant activity (Amabeoku and Kinyua, 2010; Amabeoku et al., 2014). All the 
experiments were carried out in a quiet laboratory at an ambient temperature of 22±1°C during 
the period between 09h00 -17h00 on each a day of the experiment. 
3.7   Acute toxicity study 
The method of El Hilaly et al. (2004) and the method described by Lorke (1983) modified by 
Ojewole (2006) were used for the acute toxicity study of T. violacea. The acute toxicity study 
was carried out to determine the median lethal dose (LD50) of the plant extract. Mice were 
fasted for 16 hours and then randomly divided into groups of eight mice per cage. Graded doses 
of the plant extract (100, 200, 400, 800, 1200, 1600, 2000, 2400, 2800, 3200, 3600 and 4000 
mg/kg) were separately administered orally by means of a bulbed steel needle to mice in each 
test group. The control group received 0.25 ml per os (p.o.) of physiological saline by means of a 
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bulbed steel needle. The mice were then allowed free access to food and water and observed for 
5 days for signs of acute toxicity including death. In the case of any death occurring at any dose 
range within the 5 days observation period, log dose-response curves would be constructed for 
the plant extract from which the median lethal dose would be calculated. 
3.8     Statistical analysis: 
 
The results obtained from this study were analysed using one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison test (GraphPad Prism, version 5.0, 
GraphPad software, Inc., San Diego Cap2130, USA). The number of animals convulsing was 
analysed using the Chi-squared test (Bienvenu et al., 2002). The data obtained was expressed as 
mean ± SEM. P-values of less than 5% (p<0.05) were considered statistically significant. 
3.9      Ethical considerations 
 
The experimental protocol used in this study was approved (14/7/46) by the University of the 
Western Cape Animal Ethics Committee, Bellville 7535, South Africa and complies with to the 
University’s Regulations on animal experiments. 
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Chapter 4 
Results 
 
4.1        Phytochemical analysis 
The phytochemical quantitative analysis of the dried leaf powder of T. violacea showed that the 
plant species contain the following chemical components: alkaloids, saponins, reducing sugars, 
flavonoids, cardiac glycosides, triterpene steroids, quinones and tannins (Table 1). 
Table 1. Phytochemical analysis of the dried powdered leaf of T. violacea 
Compounds       Results 
Alkaloids       + 
Cardiac glycosides      + 
Flavonoids       + 
Reducing sugars      + 
Saponins       + 
Tannins       + 
Triterpene steroids      + 
Quinones       + 
Key:  + = Positive; - = Negative 
4.2 Pharmacological activity assessment 
4.2.1 Anticonvulsant activity 
4.2.1.1     Effects of methanolic leaf extracts of T. violacea on PTZ-induced tonic convulsion 
PTZ (100 mg/kg, i.p.) elicited tonic convulsion in all the eight mice administered with the 
convulsant agent. The methanolic leaf extract of T. violacea (100 mg/kg, i.p.) did not 
significantly affect the onset or incidence of PTZ (100 mg/kg, i.p.)-induced tonic convulsion. 
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The doses of 200 (mg/kg, i.p.) and 400 (mg/kg, i.p.) of the methanolic leaf extract of T. Violacae 
significantly delayed the onset of PTZ (100 mg/kg, i.p.)-induced tonic convulsion in a dose-
dependent manner. The methanolic leaf extract of the plant species (200 mg/kg, i.p.) did not 
affect the incidence of PTZ (100 mg/kg, i.p.)-induced tonic convulsion while 400 mg/kg (i.p.) 
protected 12.5% of mice against the tonic convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam 
(0.5mg/kg, i.p.) and muscimol (2 mg/kg, i.p.) significantly delayed the onset of PTZ (100 mg/kg, 
i.p.)-induced tonic convulsion and also significantly reduced the number of animals convulsing. 
Both phenobarbitone (12 mg/kg, i.p.) and diazepam protected 100% of mice against the tonic 
convulsion respectively. Muscimol (2 mg/kg, i.p.) protected 62.5% of mice against PTZ 
(100mg/kg, i.p.)-induced tonic convulsion while Muscimol (0.2 mg/kg, i.p.) did not significantly 
affect the onset or incidence of PTZ (100 mg/kg, i.p.)-induced tonic convulsion. However, 
combined therapy of sub-effective doses of the methanolic leaf extract of T. violacea (100 
mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p.) significantly delayed the onset of PTZ (100mg/kg, 
i.p.)-induced tonic convulsion but did not significantly reduce the number of animals convulsing. 
The combined therapy of sub-effective doses of the methanolic leaf extract of T. violacea (100 
mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p.) protected 25% of mice against the tonic convulsion. 
Phenytoin (30mg/kg, i.p.) or DMSO (0.25 ml, i.p.) did not significantly affect the onset or 
incidence of PTZ (100 mg/kg, i.p.)-induced tonic convulsion (Table 2). 
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Table 2.     Effect of leaf methanol extract of Tulbaghia violacea (TV) on pentylenetetrazole 
(PTZ)-induced tonic convulsion in mice 
Dose (mg /kg) No. convulsed / 
No. used 
Percentage    
Protection  
Onset of tonic 
convulsion (min) 
PTZ TV Pheno 
barbitone 
Diazepam Phenytoin Muscimol DMSO  (%) Mean     ±     SEM 
100 - - - - - - 8/8  2.50 0.33 
100 100 - - - - - 8/8 0 9.0 2.89 
100 200 - - - - - 8/8 0 13.63* 2.51 
100 400 - - - - - 7/8 12.5 18.38* 1.99 
100 - 12 - - - -    0/8++ 100 0*  
100 - - 0.5 - - -    0/8++ 100 0*  
100 - - - 30 - - 8/8 0 2.41 0.66 
100 - - - - 2 -  3/8+ 62.5 21.0* 4.42 
100 - - - - 0.2 - 8/8 0 2.88 0.52 
100 100 - - - 0.2 - 6/8 25 14.50* 4.11 
100 - - - - - 0.25ml 8/8 0 2.75 0.37 
 
*p<0.001 compared to PTZ (100 mg/kg, i.p.) control, ANOVA (n=8) 
+p<0.05, ++p<0.001compared to PTZ (100 mg/kg. i.p.) control, Chi-squared test (n=8)  
DMSO: Dimethylsulfoxide 
 
 
4.2.1.2     Effect of leaf methanol extract of T. violacea on bicuculline-induced tonic 
convulsion 
Bicuculline (30 mg/kg, i.p.) produced tonic convulsion in all eight mice used for theexperiment. 
Methanolic leaf extracts of T. violacea (100-400 mg/kg, i.p.) significantly and dose-dependently 
delayed the onset of tonic convulsion produced by bicuculline (30 mg/kg, i.p.) but did not affect 
the incidence of the convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.) or 
muscimol (2 mg/kg, i.p.) significantly delayed the onset of bicuculline (30 mg/kg, i.p.)-induced 
tonic convulsion and also significantly reduced the number of animals convulsing. 
Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.) or muscimol (2 mg/kg, i.p.) 
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protected 87.5% of mice against bicuculline (30 mg/kg, i.p.)-induced tonic convulsion. 
Phenytoin (30 mg/kg, i.p.) and DMSO (0, 25 ml, i.p.) did not significantly affect the onset or 
incidence of bicuculline (30 mg/kg, i.p.)-induced tonic convulsion (Table 3). 
 
Table 3:    Effect of leaf methanol extract of Tulbaghia violacea (TV) on bicuculline (BIC)-
induced tonic convulsion in mice 
Dose (mg /kg) No. 
convulsed/
No. used 
Percentage    
Protection  
Onset of tonic 
convulsion (min) 
BIC TV Pheno 
barbitone 
Diazepam Phenytoin Muscimol DMSO  (%) Mean     ±    SEM 
30 - - - - - - 8/8  2.38 0.42 
30 100 - - - - - 8/8 0 5.63* 0.38 
30 200 - - - - - 8/8 0 5.88* 0.30 
30 400 - - - - - 8/8 0 10.28** 1.37 
30 - 12 - - - - 1/8+ 87.5 15.37** 0.89 
30 - - 0.5 - - - 1/8+ 87.5 19.25** 1.12 
30 - - - 30 - - 8/8 0 2.44 0.51 
30 - - - - 2 - 1/8+ 87.5 20.02** 1.27 
30 - - - - - 0.25ml 8/8 0 2.34 0.60 
 
*P<0.01, **P<0.001 compared to bicuculline (30 mg/kg, i.p.) control, ANOVA (n=8) 
+p<0.005 compared to bicuculline (30 mg/kg, i.p.) control, Chi-squared test (n=8) 
DMSO:  Dimethylsulfoxide 
 
4.2.1.3     Effect of leaf methanol extract of T. violacea on PCN-inducedtonic convulsion 
 
PCN (20 mg/kg, i.p.) elicited tonic convulsion in 100% of mice used for the experiment. The 
methanolic leaf extract of T. violacea (100, 200 and 400 mg/kg, i.p.) significantly and dose-
dependently delayed the onset of the PCN (20 mg/kg, i.p.)-elicited tonic convulsion but did not 
significantly alter the incidence of the convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam 
(0.5 mg/kg, i.p.) and muscimol (2 mg/kg, i.p.) significantly delayed the onset of PCN (20 mg/kg, 
i.p.)-induced tonic convulsion and also significantly reduced the number of animals convulsing. 
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Both diazepam (0.5 mg/kg, i.p.) and muscimol (2 mg/kg, i.p.) protected 87.5% of the animals 
against PCN (20 mg/kg, i.p.)-elicited tonic convulsion. Phenobarbitone (12 mg/kg, i.p.) protected 
75% of mice against tonic convulsion while Phenytoin (30 mg/kg, i.p.) and DMSO (0.25 ml, i.p.) 
did not significantly affect the onset or incidence of PCN (20 mg/kg, i.p.)-induced tonic 
convulsion (Table 4). 
Table 4:     Effect of leaf methanol extract of Tulbaghia violacea (TV) on picrotoxin (PCN)-
induced tonic convulsion in mice 
Dose (mg /kg) No. convulsed/ 
No. used 
Percentage    
Protection  
Onset of tonic 
convulsion (min) 
PCN TV Pheno 
barbitone 
Diazepam Phenytoin Muscimol DMSO  (%) Mean      ±      SEM 
20 - - - - - - 8/8  8.50 0.42 
20 100 - - - - - 8/8 0 11.38* 1.07 
20 200 - - - - - 8/8 0 13.00* 0.73 
20 400 - - - - - 8/8 0 18.00** 0.91 
20 - 12 - - - - 2/8+ 75 21.33** 1.02 
20 - - 0.5 - - - 1/8++ 87.5 19.86** 0.95 
20 - - - 30 - - 8/8 0 8.64 0.82 
20 - - - - 2 - 1/8++ 87.5 22.75** 1.16 
20 - - - - - 0.25ml 8/8 0 8.73 0.59 
*p<0.01, **p<0.001 compared to picrotoxin (20mg/kg, i.p.) control, ANOVA (n=8). 
+p<0.01, ++p<0.005, compared to picrotoxin (20mg/kg, i.p.) control, Chi-squared test (n=8) 
DMSO: Dimethylsulfoxide. 
4.2.1.4     Effect of leaf methanol extract of T. violacea on STN-induced tonic convulsion 
 
Strychnine (2 mg/kg, i.p.) produced tonic convulsion in all the eight mice used for the 
experiment. The methanolic leaf extract of T. violacea (200 and 400 mg/kg, i.p.) significantly 
delayed the onset of STN (2 mg/kg, i.p.)-induced tonic convulsion but did not significantly affect 
the number of mice convulsing. The methanolic leaf extract of T. violacea (100 mg/kg, i.p.) did 
not significantly affect the onset or incidence of STN (2 mg/kg, i.p.)-induced tonic convulsion.  
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Phenobarbitone (12 mg/kg, i.p.) significantly delayed the onset of STN (2 mg/kg, i.p.)-induced 
tonic convulsion and also significantly protected 62.5% of the mice against STN (2 mg/kg, i.p.)-
induced tonic convulsion.  
Diazepam (0.5 mg/kg, i.p.), phenytoin (30 mg/kg, i.p.) or DMSO (0.25 ml, i.p.) did not 
significantly delay the onset of STN (2 mg/kg, i.p.)-induced tonic convulsion and did not also 
significantly affect the number of mice convulsing (Table 5). 
Table 5: Effect of leaf methanol extract of T. violacea on strychnine (STN)-induced tonic 
convulsion in mice 
Dose (mg /kg) No. 
convulsed/ 
No. used 
Percentage 
Protection  
 
  
STN TV Pheno-
barbitone 
Diazepam Phenytoin DMSO  (%) Mean  ±   SEM 
2 - - - - - 8/8  2.63 0.26 
2 100 - - - - 8/8 0 2.75 0.16 
2 200 - - - - 8/8 0 4.13* 0.23 
2 400 - - - - 8/8 0 3.88* 0.13 
2 - 12 - - - 3/8+ 75 16.72** 1.50 
2 - - 0.5 - - 8/8 0 2.6 0.85 
2 - - - 30 - 8/8 0 2.57 0.34 
2 - - - - 0.25ml 8/8 0 8.73 0.59 
*p<0.05, **p<0.001 compared to strychnine (2 mg/kg, i.p.) control, ANOVA (n=8). 
+p<0.05compared to strychnine (2 mg/kg, i.p.) control, Chi-squared test (n=8). 
DMSO: Dimethylsulfoxide. 
4.2.1.5      Effect of leaf methanol extract of T. violaceaon NMDLA-induced seizures 
 
The dose of 400 mg/kg (i.p.) of N-methyl-DL-aspartic acid (NMDLA) produced tonic 
convulsion in 100% of mice used. The methanolic leaf extract of T.violacea (100, 200 and 400 
mg/kg, i.p.) significantly and dose-dependently delayed the onset of NMDLA (400 mg/kg, i.p.)-
induced tonic convulsion but did not significantly affect the incidence of the tonic convulsion. 
LY233053 (5 mg/kg, i.p.) significantly delayed the onset of NMDLA (400 mg/kg, i.p.)-induced 
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tonic convulsion and significantly reduced the number of animals convulsing. The dose of 5 
mg/kg (i.p.) of LY233053 protected 87.5% of mice against NMDLA (400 mg/kg, i.p.) induced 
tonic convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.), phenytoin (30 
mg/kg, i.p.) and DMSO (0.25 ml, i.p.) did not significantly affect the onset of NMDLA (400 
mg/kg, i.p.)-induced tonic convulsion or the incidence of the tonic convulsion (Table 6). 
Table 6: Effect of leaf methanol extract of Tulbaghia violacea (TV) On N-methyl-DL aspartic acid 
(NMDLA)-induced tonic convulsion in mice 
Dose (mg /kg) No. 
convulsed/ 
No. used 
Percentage    
Protection  
Onset of tonic 
convulsion (min) 
NMDLA TV Pheno 
barbitone 
Diazepam Phenyt
oin 
LY 
233053 
DMSO  (%) Mean    ±  SEM 
400 - - - - - - 8/8  4.38 0.32 
400 100 - - - - - 8/8 0 7.75* 0.37 
400 200 - - - - - 8/8 0 9.75** 0.70 
400 400 - - - - - 8/8 0 14.13*** 0.41 
400 - 12 - - - - 8/8 0 4.22 0.75 
400 - - 0.5 - - - 8/8 0 4.51 0.37 
400 - - - 30 - - 8/8 0 4.57 0.42 
400 - - - - 5 - 1/8+ 87.5 20.08*** 0.94 
400 - - - - - 0.25ml 8/8 0 4.33 0.29 
*P<0.01, **p<0.005, ***p<0.001 compared to NMDLA (400mg/kg, i.p.) control, ANOVA (n=8)  
+p<0.005 compared to NMDLA (400mg/kg, i.p.) control, Chi-squared test (n=8)  
 DMSO: Dimethylsulfoxide 
4.3      Acute Toxicity 
 
The methanolic leaf extract of T. violacea (100–4000 mg/kg, p.o.) produced no signs of acute 
toxicity or death in mice after 5 days of observation. The highest dose tested, 4000 mg/kg (p.o.), 
is taken as the no-adverse-effect-level (NOAEL) since no signs of acute toxicity were observed 
at this dose level. The LD50 obtained for T. violacea following oral administration may probably 
be greater than 4000 mg/kg. 
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4.4      HPLC Analysis.  
 
The HPLC fingerprint of the leaf methanol extract of Tulbaghia violacea showed distinct peaks 
at the following retention times, 2.911, 3.269, 4.010, 7.597, and 15.122 minutes (Figure 8). 
 
 
Figure 8: HPLC fingerprint of methanol extract of Tulbaghia violacea 
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Chapter 5 
Discussion 
The study evaluated the anti-convulsant activity of the leaf methanol extract of Tulbaghia 
violacea with a view to scientifically scrutinize the effectiveness of the plant species in the 
treatment of epilepsy as claimed by traditional medicine practitioners. The study also 
investigated possible mechanism(s) of the plant species’ anticonvulsant activity by using 
convulsant agents known to affect certain neurotransmitters in the central nervous system (CNS) 
implicated in epilepsy. The present study shows that PTZ (100 mg/kg, i.p.), bicuculline (30 
mg/kg, i.p.), PCN (12 mg/kg, i.p.), STN or NMDLA (400 mg/kg, i.p.) produced tonic convulsion 
in all the mice used. The methanolic leaf extract of T. violacea (200-400 mg/kg, i.p.) was found 
to attenuate the tonic convulsions produced by PTZ and STN. Similarly, the 100-400 mg/kg (i.p.) 
dose also attenuated tonic convulsions produced by bicuculline, PCN and NMDLA-induced 
tonic convulsion. Phenobarbitone (12 mg/kg, i.p.) and diazepam (0.5 mg/kg, i.p.) attenuated the 
tonic convulsions produced by PTZ, bicuculline and PCN but did not affect NMDLA-induced 
tonic convulsion. Muscimol (2 mg/kg, i.p.) attenuated the tonic convulsions produced by PTZ, 
bicuculline and PCN. Phenytoin (30 mg/kg, i.p.) did not affect the tonic convulsions produced by 
PTZ, bicuculline, PCN, STN or NMDLA whereas LY23350 (5 mg/kg, i.p.) attenuated NMDLA-
induced tonic convulsion and Phenobarbitone (12 mg/kg, i.p.) also attenuated the tonic 
convulsions produced by STN.  
An imbalance between gamma amino butyric acid (GABA), a major inhibitory neurotransmitter 
and glutamic acid, an excitatory neurotransmitter in the brain underpins epilepsy. The inhibition 
of GABA mediated inhibition at GABAA receptors and the enhancement of glutamic acid 
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neurotransmission at NMDA receptors in the brain may cause convulsion (Olsen 1981, Waller et 
al., 2005, Rang etal., 2015). PTZ is thought to act by blocking GABAA receptors thus inhibiting 
GABA neurotransmitter (De Sarro et al., 1999, Rang et al., 2015). According to Waller et al., 
2005 and Rang et al., 2015, the standard AEDs, phenobarbitone and diazepam are known to act 
by enhancing GABA neurotransmission in the brain by respectively increasing the duration and 
frequency of the opening of GABAA receptor-linked chloride channels in the GABAA receptor- 
chloride ionophore complex to facilitate chloride ion conductance into the brain. It is not 
surprising therefore that phenobarbitone and diazepam attenuated PTZ-induced tonic convulsion 
in the present study. Phenytoin, another standard AED, acts by blocking the entry of sodium ions 
into brain cells and thus, inhibiting the generation of repetitive action potential (Waller et al., 
2005 and Rang et al., 2015) and therefore, did not affect PTZ-inducedtonic convulsion in this 
study. According to Lança (1998) and Rang et al. (2015), muscimol, a selective and powerful 
GABAA receptor agonist, acts by interacting with GABAA receptors in the brain to mimic the 
effects of GABA. Accordingly, muscimol significantly attenuated PTZ-induced tonic convulsion 
in mice. 
In this study, the methanolic leaf extracts of T. violacea appeared to attenuate PTZ-induced tonic 
convulsion suggesting that T. violacea could be affecting with the anti-convulsant activity of 
GABA. The combined therapy of sub-effective doses of T. violacea and muscimol, significantly 
attenuated PTZ-induced tonic convulsion, suggesting that GABA mechanism may be involved in 
the anti-convulsant activity of T. violacea. According to Rang et al. (2015), bicuculline, a 
GABAA receptor antagonist, produces its convulsant activity by blocking GABAA receptors thus 
inhibiting GABA neurotransmission in the brain. In this study, bicuculline produced tonic 
convulsion which was attenuated by phenobarbitone and diazepam, both of which are known to 
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enhance GABA neurotransmission. Furthermore, muscimol, a specific GABAA receptor agonist, 
known to mimic the effect of GABA at GABAA receptors in the brain was shown to attenuate 
bicuculline-induced tonic convulsion. The methanolic leaf extract of T. violacea also attenuated 
bicuculline-induced tonic convulsion while Phenytoin (known to exert its anti-epileptic effects 
by blocking sodium ion entry into the brain), did not attenuate bicuculline-induced tonic 
convulsion. These findings further support the suggestion that GABA mechanism may be 
involved in the anti-convulsant activity of Tulbaghia violacea. 
PCN is known to produce convulsion by blocking GABAA receptor-linked chloride ion channels 
to prevent the entry of chloride ions into the brain to inhibit GABA-mediated inhibition. The 
present study shows that PCN-induced tonic convulsion in mice was attenuated by 
phenobarbitone and diazepam, both of which are known to enhance GABA neurotransmission in 
the brain. Muscimol, a specific GABAA receptor agonist, known to mimic the effect of GABA at 
GABAA receptors, also attenuated PCN-induced tonic convulsion. Phenytoin, on the other hand, 
did not affect PCN-induced tonic convulsion. This drug is known to produce its anti-convulsant 
effects by blocking sodium ion entry into the brain (Rang et al., 2015). The methanolic leaf 
extract of T. violacea also attenuated PCN-induced tonic convulsion further indicating that 
GABA mechanism may be involved in the anti-convulsant activity of T. violacea. 
Rang et al. (2015), suggested that STN produces convulsion by blocking receptors for glycine in 
the brain. In this study, phenobarbitone and the methanolic leaf extract of T. violacea attenuated 
STN-induced tonic convulsion, suggesting that glycine mechanism may also be involved in the 
anti-convulsant activity of T. violacea. Rang etal. (2015) have reported that phenobarbitone may 
produce its anticonvulsant activity by different mechanisms. It is possible that phenobarbitone 
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may be producing its anti-convulsant activity by enhancing glycinergic neurotransmission in the 
brain. Benzodiazepines have been shown not to alter STN-induced convulsion in experimental 
animals (Rang et al., 2015). However, of moderate to high doses of phenobarbitone (i.v), 
diazepam (i.v) and phenytoin (i.v) have been used historically to prevent strychnine convulsion 
in strychnine poisoning in humans (Lambert et al., 1981, Boyd et al., 1983). 
According to Chapman and Meldrum (1993), Besancon et al. (2008) and Rang et al. (2012), N-
Methyl-DL-aspartic acid (NMDLA) produces its anti-convulsant effects by specifically 
stimulating NMDA receptors to mimic the action of glutamate, the excitatory neurotransmitter in 
the brain. The present study shows that phenobarbitone and diazepam (both of which are known 
to enhance GABA neurotransmission in the brain) did not affect NMDLA-induced tonic 
convulsion in mice whereas LY233053 attenuated NMDLA-induced tonic convulsion. On the 
other hand, Phenytoin known to exert its anticonvulsant effect by blocking sodium ion entry into 
the brain also did not alter NMDLA-induced tonic convulsion.According to Madden et al. (1992) 
and Borowicz et al. (1996), LY233053, is a competitive NMDA receptor antagonist, which acts 
by blocking the effects of glutamic acid at NMDA receptors. In this study, the methanolic leaf 
extract of T. violacea was found to attenuate NMDLA-induced tonic convulsion. These findings 
suggest the possible involvement of glutamic acid mechanism(s) in the anticonvulsant activity of 
T. violacea. 
In this study, the phytochemical qualitative analysis of the dried leaf extract of T. violacea 
revealed the presence of alkaloids, saponins, reducing sugars, flavonoids cardiac glycosides, 
triterpene steroids, quinones and tannins. Alkaloids, flavonoids, saponins triterpene steroids have 
been shown in different studies to possess anti-convulsant activities (Chauhan et al. 1988, 
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Mimaki et al., 1997, Van Heerden et al., 2002, Muazu and Kaita 2008, Ibrahim et al., 2008, 
Singh et al., 2012). It is therefore possible that these secondary metabolites may be contributing 
to the anti-convulsant activity of T. violacea. The results obtained from the acute toxicity study 
carried out showed that following oral administration of the methanolic leaf extract to mice, the 
LD50 may be greater than 4000 mg/kg which suggests that T. violacea is safe and non-toxic to 
mice. The HPLC finger print obtained for T. violacea revealed the presence of characteristic 
peaks at 350 nm which may be used to identify the exact species of T. violacea. 
5.1     Conclusion 
 
The results obtained from this study indicate that the methanolic leaf extract of T. violacea has 
anti-convulsant activity which may involve GABA, glutamic acid and glycine mechanisms. 
Secondary metabolites such as saponins, triterpene steroids, alkaloids and flavonoids found in 
the leaves of the plant species may also in part be contributing to the observed anti-convulsant 
activity. The relatively high LD50 value obtained for the plant species following oral 
administration shows that it is safe in mice. These findings justify the use of T. violacea by 
traditional practitioners in the management and treatment of epilepsy. However, further studies 
are needed to fully elucidate the mechanism(s) of its anti-convulsant activity as well as establish 
its toxicity and safety profile. 
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